See more : Bill Identity Limited (BID.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Standard BioTools Inc. (FLDM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Standard BioTools Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Tekkorp Digital Acquisition Corp. (TEKK) Income Statement Analysis – Financial Results
- Infinite Finance Co., Ltd. (6958.TWO) Income Statement Analysis – Financial Results
- Greenwind Holdings Inc. (NEWG) Income Statement Analysis – Financial Results
- Shanghai YongLi Belting Co., Ltd (300230.SZ) Income Statement Analysis – Financial Results
- Coastal Financial Corporation (CCB) Income Statement Analysis – Financial Results
Standard BioTools Inc. (FLDM)
About Standard BioTools Inc.
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.34M | 97.95M | 130.58M | 138.14M | 117.24M | 112.96M | 101.94M | 104.45M | 114.71M | 116.46M | 71.18M | 52.33M | 42.87M | 33.56M | 25.41M | 15.35M | 7.28M | 6.40M | 130.58M |
| Cost of Revenue | 55.89M | 60.90M | 61.21M | 54.82M | 52.96M | 51.32M | 49.96M | 46.01M | 46.63M | 42.85M | 20.08M | 15.33M | 13.19M | 11.58M | 11.49M | 8.36M | 3.51M | 2.77M | 53.32M |
| Gross Profit | 50.45M | 37.05M | 69.37M | 83.33M | 64.28M | 61.65M | 51.98M | 58.44M | 68.08M | 73.61M | 51.10M | 37.01M | 29.67M | 21.98M | 13.93M | 6.98M | 3.76M | 3.63M | 77.27M |
| Gross Profit Ratio | 47.44% | 37.83% | 53.13% | 60.32% | 54.83% | 54.57% | 50.99% | 55.95% | 59.35% | 63.21% | 71.79% | 70.72% | 69.23% | 65.49% | 54.80% | 45.50% | 51.70% | 56.66% | 59.17% |
| Research & Development | 25.95M | 38.50M | 37.94M | 36.46M | 31.64M | 30.03M | 30.83M | 38.42M | 39.26M | 43.42M | 19.73M | 16.60M | 13.94M | 13.01M | 12.32M | 14.02M | 14.39M | 15.59M | 37.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.54M | 114.76M | 98.89M | 97.90M | 84.48M | 79.78M | 79.52M | 93.21M | 82.96M | 71.32M | 48.06M | 38.48M | 31.30M | 23.55M | 19.65M | 22.51M | 12.90M | 9.70M | 98.89M |
| Other Expenses | 0.00 | -12.31M | 7.63M | 507.00K | 1.43M | 637.00K | 385.00K | -1.17M | -1.16M | -857.00K | 502.00K | -189.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.89M |
| Operating Expenses | 113.49M | 153.26M | 136.83M | 134.36M | 116.12M | 109.81M | 110.34M | 131.63M | 122.22M | 114.75M | 67.79M | 55.08M | 45.24M | 36.55M | 31.96M | 36.53M | 27.29M | 25.29M | 144.73M |
| Cost & Expenses | 169.38M | 214.15M | 198.04M | 189.18M | 169.08M | 161.13M | 160.30M | 177.64M | 168.85M | 157.60M | 87.87M | 70.41M | 58.43M | 48.13M | 43.45M | 44.89M | 30.80M | 28.06M | 198.04M |
| Interest Income | 0.00 | 4.33M | 291.00K | 307.00K | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.00K | 37.00K | 766.00K | 1.14M | 565.00K | 0.00 |
| Interest Expense | 4.57M | 4.33M | 3.82M | 3.57M | 4.28M | 13.89M | 5.82M | 5.82M | 5.81M | 5.34M | 14.00K | 628.00K | 3.10M | 2.16M | 2.88M | 2.03M | 2.79M | 2.26M | -3.82M |
| Depreciation & Amortization | 15.18M | 15.03M | 16.07M | 17.94M | 15.81M | 16.50M | 18.30M | 17.94M | 16.12M | 4.06M | 2.55M | 1.48M | 1.06M | 1.50M | 1.94M | 1.97M | 2.14M | 1.46M | 0.00 |
| EBITDA | -54.46M | -173.57M | -43.77M | -34.61M | -46.62M | -31.03M | -39.68M | -56.42M | -32.87M | -38.50M | -13.82M | -16.78M | -18.14M | -13.52M | -14.67M | -26.12M | -20.91M | -19.83M | -67.46M |
| EBITDA Ratio | -51.21% | -115.87% | -33.89% | -25.05% | -29.51% | -27.40% | -38.62% | -54.02% | -34.16% | -32.58% | -19.15% | -32.06% | -33.84% | -38.92% | -63.20% | -174.69% | -278.32% | -306.96% | -51.66% |
| Operating Income | -76.60M | -116.21M | -67.46M | -51.04M | -51.84M | -48.16M | -58.36M | -73.19M | -50.16M | -51.84M | -17.95M | -18.07M | -18.57M | -14.57M | -18.04M | -29.54M | -23.53M | -21.66M | -67.46M |
| Operating Income Ratio | -72.03% | -118.64% | -51.66% | -36.94% | -44.22% | -42.64% | -57.25% | -70.07% | -43.72% | -44.51% | -25.22% | -34.53% | -43.31% | -43.42% | -70.98% | -192.50% | -323.38% | -338.59% | -51.66% |
| Total Other Income/Expenses | 2.40M | -76.72M | 3.80M | -3.07M | -14.87M | -13.26M | -5.44M | -6.99M | -4.64M | -5.87M | 2.26M | -817.00K | -3.74M | -2.25M | -1.14M | -103.00K | -1.82M | -1.89M | 3.80M |
| Income Before Tax | -74.20M | -192.93M | -63.66M | -54.10M | -66.71M | -61.42M | -63.80M | -80.18M | -54.79M | -57.71M | -15.69M | -18.89M | -22.30M | -16.82M | -19.18M | -29.65M | -25.35M | -23.55M | -63.66M |
| Income Before Tax Ratio | -69.78% | -196.97% | -48.75% | -39.16% | -56.89% | -54.37% | -62.59% | -76.76% | -47.76% | -49.55% | -22.03% | -36.09% | -52.03% | -50.12% | -75.47% | -193.17% | -348.40% | -368.13% | -48.75% |
| Income Tax Expense | 452.00K | -2.83M | -4.42M | -1.08M | -1.92M | -2.41M | -3.26M | -4.19M | -1.48M | -4.88M | 137.00K | 136.00K | 166.00K | 83.00K | -50.00K | -147.00K | 105.00K | 194.00K | -4.42M |
| Net Income | -74.66M | -190.10M | -59.24M | -53.02M | -64.79M | -59.01M | -60.54M | -75.99M | -53.32M | -52.83M | -15.82M | -19.02M | -22.47M | -16.90M | -19.13M | -29.50M | -25.45M | -23.55M | -59.24M |
| Net Income Ratio | -70.21% | -194.08% | -45.36% | -38.38% | -55.26% | -52.24% | -59.38% | -72.75% | -46.48% | -45.36% | -22.23% | -36.35% | -52.42% | -50.36% | -75.27% | -192.21% | -349.84% | -368.13% | -45.36% |
| EPS | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
| EPS Diluted | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
| Weighted Avg Shares Out | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
| Weighted Avg Shares Out (Dil) | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022
Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion
Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results
Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors
Fluidigm Corporation: Investment Opportunity
Source: https://incomestatements.info
Category: Stock Reports